FAQs & How to use this site
Home | About Us | Contact Us
The Front Line
The Front Line: Charles D. Blanke, MD, SWOG Chair
ABOUT

PREVIOUS POSTS October 2017

September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013

SWOG at ASCO 2015

May 29, 2015 - ASCO 2015 is underway, and as in previous years, SWOG is well-represented. With 20 SWOG-led abstracts this year, and an additional 11 SWOG-associated abstracts, our numbers for 2015 compare favorably to our numbers from the past few years.

ASCO Annual Meeting Abstracts 2011-2015

YEAR

2015

2014

2013

2012

2011

SWOG led/overall total

20/31

15/24

9/13

27/29

10/14

SWOG led/total ORAL presentations

4/10

4/10

2/2

8/10

4/6

You can see the full list of SWOG-related abstracts and their times and locations online, but here are the details on the four SWOG-led oral presentations being given in Chicago (NB: 80405 was co-led by SWOG and the Alliance; two additional oral presentations came out of secondary analyses not coordinated by SWOG).

SWOG-led Abstracts Presented Orally at ASCO 2015

Study

Abstract Title/Abstract Link

Authors

Abstract Number

Session Time & Place

S0307

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/ Alliance/ ECOG-ACRIN/ NCIC Clinical Trials Group/ NRG Oncology study S0307

JR Gralow, et al.

503

Session: Breast Cancer-HER2/ER

Date/Time: 6/1/15, 8-11:00 am (9-9:12 am)

Location: N Hall B1

S0518

SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients

JC Yao, et al.

4004

Session: Gastrointestinal (Non-colorectal)

Date/Time: 5/31/15, 8-11:00 am (9:12-9:24 am)

Location: E Hall D2

S9346

Long term consequences of intermittent and continuous androgen deprivation in patients with metastatic prostate cancer

DL Hershman, et al.

5008

Session: Prostate

Date/Time: 5/31/15, 9:45 am-12:30 pm (12:09 -12:21 pm)

Location: E Arie Crown Theater

Multiple

Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group

C Savage Bennette, et al.

6506

Session: Health Services Research and Quality of Care

Date/Time: 5/30/15,1:15-4:15 PM

(3:15- 3:27 PM)

Location: S102

Of course, a count of abstracts presented is only one metric we might use to quantify SWOG's presence and impact at the annual ASCO meeting. We could also compile a list of sessions chaired or keynoted by SWOG leaders and other active group members. They may or may not be involved with sessions highlighting SWOG research, but their selection to officiate speaks to the high regard our investigators are held in by their peers/other experts. The lists below are in no way comprehensive, but here are a few such sessions that were held on Friday, May 29:

  • Breast Committee Chair Gabriel Hortobagyi co-chaired a special Global Oncology Symposium
  • Young Investigators Task Force Chair Cathy Eng chaired a ticketed Clinical Problems in Oncology Session titled "Treating Newly Diagnosed Metastatic Colorectal Cancer: The Role of Chemotherapy, Ablation, and Surgery"
  • SWOG Study Chair for CTSU/9177 Michelle A. Fanale chaired the education session "Incorporating Novel Agents into Lymphoma Therapy: Value in Everyday Practice"
  • Lung-MAP Co-PI Roy Herbst chaired an educational symposium titled "Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations"

And here are a number of sessions you can hopefully still catch, if you're in Chicago:

  • Outgoing Prevention Committee Co-Chair Powel Brown chairs an education session titled "Breast Cancer Chemoprevention: Proven but Publicly Ignored -- An Update of Benefit and Risk Data" (Sat, May 30, 8-9:15 am, S100bc)
  • Lung Committee Chair David Gandara is a keynote speaker at an educational symposium titled "Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance" (Sun, May 31, 7-9 pm, Sheraton Chicago, Ballroom VI)
  • GU Committee Vice-Chair Nicholas Vogelzang chairs an education session on "Integrating New Approaches in Complicated Bladder Cancer" (Mon, June 1, 8-9:15 am, E Hall D2)
  • Thomas Semrad, Co-PI on S0819, co-chairs a GI poster discussion session on colorectal cancer (Mon, June 1, 1:15-2:30 pm, E Hall D1)
  • Lung-MAP Co-PI Vassiliki Papadimitrakopoulou chairs an oral abstract session on head and neck cancer (Mon, June 1, 1:15-4:15 pm, S100bc)
  • S1211 Study Chair Saad Usmani chairs an education session on "Personalized Therapy for Multiple Myeloma in a Value-Oriented Environment" (Tues, June 2, 8-9:15 am, E354b). Later that morning, he co-chairs an oral abstract myeloma session (Tues, June 2, 9:45 am - 12:45 pm, E354b)

I am unbelievably proud of the SWOG researchers and faculty. If you're in Chicago for ASCO 2015, I hope to see you here. If you're not, I hope you take an opportunity to review some of the results of the wonderful work we do, via the ASCO website or JCO.

 

 
     
SWOG Logo Disclaimer | Copyright ©2000-2017 SWOG. All rights reserved.
Design by nuMedia Group Inc. | Hosting by WorldPost Technologies, Inc.
SWOG is FISMA CertifiedSWOG is FISMA Certified